Maria Grazia D’Errigo

Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial

Esther Natalie Olíva, Caterina Alati, Valeria Santini et al. · The Lancet Haematology · 2017 · 162 citations · Full text

Medicine, Hematology, Pharmacotherapy +8

RNA-protein interactions in the control of stability and localization of messenger RNA (review).

Maria Grazia D’Errigo, Alessandro Cestelli, Giovanni Savettieri et al. · International Journal of Molecular Medicine · 2000 · 117 citations

Life Sciences, Developmental Biology, Molecular Biology +17

Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)

Esther Natalie Olíva, Marta Riva, Pasquale Niscola et al. · Journal of Clinical Oncology · 2023 · 34 citations · Full text

Medicine, Hematology, Pharmacotherapy +16

Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy

Esther Natalie Olíva, Roberto Latagliata, Carmelo Laganà et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2013 · 30 citations

Medicine, Hematology, Pharmacotherapy +17

Changes in <i>RPS14</i> expression levels during lenalidomide treatment in Low‐ and Intermediate‐1‐risk myelodysplastic syndromes with chromosome 5q deletion

Esther N. Oliva, Maria Cuzzola, Francesco Nobile et al. · European Journal Of Haematology · 2010 · 29 citations

Life Sciences, Genetics, Hematology +17